RLAY stock forecast benefits from diversification into multiple therapeutic areas. This mitigates sector-specific risks and supports stable price action. Current RSI levels near 58 suggest the stock is not yet overbought, leaving room for upward momentum. Just because a business does not make any money, does not mean that the stock will go down. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring revenue, if you held shares since 2005, you'd have done very well indeed. But while the successes are well known, investors should not ignore the very many unprofitable companies that simply burn through all their cash and collapse. Now, the macro narrative on Wall Street is driven by how fast the Fed will reduce interest rates. Higher rates and a tight economy have broad implications for stocks. They drive cyclical sectors to low levels and prop up others such as financials and defensives. Additionally, tighter discretionary spending means that high-growth sectors like electric vehicles suffer. High interest rates also constrain sectors such as real estate, while a sluggish economy leads to others such as industrial also lagging major stock indexes. RLAY stock forecast models suggest EPS growth could hit 0.38 in the next quarter, assisted by higher R&D efficiency. With biotech indices trending higher, sentiment favors upward mobility toward $18-$19 within a 60-day horizon.